A new multi-institution study spearheaded by researchers at Florida State University and the University of California, Los Angeles suggests a tiny protein could play a major role in combating heart failure related to Duchenne muscular dystrophy (DMD), the most common lethal genetic disorder among children.
In collaboration with scientists from across the nation, FSU researchers found that increased levels of the protein sarcospan improve cardiac function by reinforcing cardiac cell membranes, which become feeble in patients with DMD.
Their findings were published in the journal JCI Insight.
The condition, which typically afflicts young boys, is caused by a mutation that prevents the body from producing dystrophin, a protein crucial to the health of skeletal, respiratory and cardiac muscles. Advances in treatment for certain types of DMD-related muscle degradation have helped to prolong patients’ lifespans. However, as DMD patients age, their heart function declines dramatically.
“Patients typically live to 20 or 30 years of age,” said lead author Michelle Parvatiyar, an assistant professor in the Department of Nutrition, Food and Exercise Sciences in FSU’s College of Human Sciences. “There have been important improvements in respiratory care, which used to be what a majority of patients would succumb to. Now, in their 20s and 30s, they’re often succumbing to cardiomyopathy. The heart is functioning with a major component of the cell membrane missing. Over time, it wears out.”
The study was part of continued efforts by UCLA biologist Rachelle H. Crosbie, the study’s corresponding author, who previously identified sarcospan as a protein that could improve mechanical support in skeletal cell membranes lacking dystrophin. Her finding buoyed DMD researchers and affirmed sarcospan’s potential as an effective tool in the fight against the condition.
“But nobody had really looked at how increasing the levels of this protein might affect the heart,” Parvatiyar said.
Using a unique mouse model with a dearth of dystrophin, Parvatiyar and her collaborators did just that.
In their study, the team found that while it’s is not a like-for-like replacement for dystrophin, an overexpression of sarcospan in cardiac cells seems to do the job of stabilizing cell membranes. Even under stress, researchers found, sarcospan overexpression was able to improve the membrane defect in dystrophin-deficient cells.
“Sarcospan doesn’t quite do the job of dystrophin, but it acts as a glue to stabilize the membrane and hold protein complexes together when dystrophin is lacking,” said Parvatiyar, explaining a concept developed by Crosbie.
Cardiac measurements confirmed that sarcospan does protect the cell membrane even when the heart is placed under stress. Study co-author and FSU College of Medicine Associate Professor Jose Pinto performed the measurements, along with FSU graduate student Karissa Dieseldorff Jones and University of Miami Miller School of Medicine research assistant Rosemeire Takeuchi Kanashiro.
In addition to serving as a kind of stabilizing glue, researchers said sarcospan could also act as a scaffold that supports other essential proteins at the cell membrane. That function could allow sarcospan to carry mini versions of dystrophin — which, in its normal state, has a long and unwieldy genetic code — to the edges of cardiac cells, where they could buttress the fragile membranes.
“The idea is that you could administer the sarcospan and the dystrophin at the same time, and the sarcospan could facilitate mini dystrophin localizing to the cell membrane and help hold those complexes in place,” Parvatiyar said.
Sarcospan’s two possible functions could augment existing DMD treatments, Parvatiyar said, or they could give rise to novel therapies that fortify weakened cardiac cell membranes and improve the quality of life for people with DMD.
In her previous position at UCLA, Parvatiyar had frequent interactions with DMD patients and their families. She said these interactions, and the unshakeable hope she’s witnessed in those suffering from DMD, continue to drive her and her colleagues in the search for new ways to combat this debilitating condition.
“Those were the first times in my life I’d ever had someone come up to me and thank me for my work,” she said. “Sometimes you can feel removed from it in the laboratory day after day. You see incremental progress. But to see people who are really yearning for help is motivating. Their positivity is incredibly inspiring.”
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Is the medication you’re taking worth its price?on February 1, 2020 at 10:09 am
This article originally appeared on Undark. Austin was three years old and Max was a newborn when their mother, Jenn McNary, learned they had a rare genetic condition called Duchenne muscular ...
- New gene correction therapy for Duchenne muscular dystrophyon January 28, 2020 at 5:01 am
Duchenne type muscular dystrophy (DMD) is the most common hereditary muscular disease among children, leaving them wheelchair-bound before the age of 12 and reducing life expectancy. Researchers at ...
- Muscular Dystrophy Association Announces 2020-2021 National Ambassador Ethan LyBrand from Alabamaon January 28, 2020 at 5:00 am
NEW YORK, Jan. 28, 2020 /PRNewswire/ -- The Muscular Dystrophy Association (MDA) named 10-year-old Ethan LyBrand as its 2020-2021 MDA National Ambassador. Ethan and his parents, Jordan and Josh ...
- Gene scissors against incurable muscular diseaseon January 28, 2020 at 12:52 am
Muscles need dystrophin in order to regenerate. Persons suffering from Duchenne muscular dystrophy lack this essential muscular protein due to mutations in the gene which is responsible for producing ...
- CRISPR gene-editing corrects muscular dystrophy in pigson January 27, 2020 at 10:59 pm
Duchenne muscular dystrophy (DMD) is one of the most common and most devastating muscular diseases, greatly reducing patients’ quality of life and life expectancy. Now, researchers in Germany have ...
- 5 Things You Should Know About Muscular Dystrophyon January 27, 2020 at 4:46 pm
Related: 'The L Word' Reboot Features Jillian Mercado as New Disabled Character The most common type of muscular dystrophy is called Duchenne muscular dystrophy, and it mainly affects young boys.
- New gene correction therapy for hereditary muscular disease among childrenon January 27, 2020 at 4:35 pm
Duchenne type muscular dystrophy (DMD) is the most common hereditary muscular disease among children, leaving them wheelchair-bound before the age of twelve and reducing life expectancy. Researchers ...
- Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophyon January 27, 2020 at 8:30 am
All prices are NET prices. VAT will be added later in the checkout. Fig. 1: Genome editing of DMDΔ52 pigs by Cas9-mediated exon 51 excision. Fig. 2: Genome editing of DMDΔ52 restores the structure and ...
- Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophyon January 24, 2020 at 2:04 am
Characterised by progressive and fatal muscular weakness and degeneration, Duchenne Muscular Dystrophy (DMD) is a rare neuromuscular disorder that arises from the loss of dystrophin at the sarcolemma ...
- FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugson January 22, 2020 at 1:35 pm
Safety concerns stymied Sarepta Therapeutics’ attempt to win FDA approval last August for golodirsen (Vyondys 53), its second Duchenne muscular dystrophy drug. But an appeal of the decision led to a ...
via Bing News